| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| General Surgery | 27 | 2024 | 211 | 6.160 |
Why?
|
| Specialties, Surgical | 8 | 2021 | 46 | 1.940 |
Why?
|
| Students, Medical | 6 | 2023 | 263 | 1.810 |
Why?
|
| Internship and Residency | 15 | 2024 | 805 | 1.810 |
Why?
|
| Societies, Medical | 10 | 2025 | 400 | 1.660 |
Why?
|
| Rib Fractures | 7 | 2022 | 23 | 1.470 |
Why?
|
| Career Choice | 4 | 2021 | 126 | 1.120 |
Why?
|
| United States | 37 | 2025 | 8098 | 1.110 |
Why?
|
| Pancreatitis | 9 | 2018 | 97 | 1.100 |
Why?
|
| Education, Medical, Graduate | 9 | 2024 | 348 | 1.090 |
Why?
|
| Surgeons | 5 | 2023 | 191 | 1.090 |
Why?
|
| Educational Measurement | 3 | 2021 | 213 | 1.040 |
Why?
|
| Humans | 144 | 2025 | 65141 | 1.040 |
Why?
|
| Minority Groups | 6 | 2021 | 141 | 1.030 |
Why?
|
| Workload | 4 | 2017 | 131 | 1.010 |
Why?
|
| Conflict of Interest | 3 | 2019 | 38 | 0.990 |
Why?
|
| Wounds, Nonpenetrating | 6 | 2025 | 116 | 0.890 |
Why?
|
| Specialization | 2 | 2016 | 82 | 0.880 |
Why?
|
| Delphi Technique | 2 | 2024 | 112 | 0.860 |
Why?
|
| Retrospective Studies | 45 | 2025 | 6865 | 0.750 |
Why?
|
| Personnel Staffing and Scheduling | 3 | 2017 | 66 | 0.720 |
Why?
|
| Male | 82 | 2025 | 31055 | 0.710 |
Why?
|
| Surgical Procedures, Operative | 7 | 2024 | 141 | 0.710 |
Why?
|
| Surgical Wound Infection | 4 | 2016 | 124 | 0.700 |
Why?
|
| Congresses as Topic | 4 | 2025 | 76 | 0.700 |
Why?
|
| Licensure, Medical | 1 | 2021 | 8 | 0.700 |
Why?
|
| Medically Underserved Area | 1 | 2021 | 31 | 0.700 |
Why?
|
| Biomedical Research | 3 | 2019 | 262 | 0.690 |
Why?
|
| Colorectal Neoplasms | 7 | 2018 | 286 | 0.690 |
Why?
|
| Leadership | 5 | 2023 | 212 | 0.680 |
Why?
|
| Education, Medical | 5 | 2022 | 182 | 0.670 |
Why?
|
| Female | 79 | 2025 | 34030 | 0.650 |
Why?
|
| Academic Medical Centers | 5 | 2020 | 306 | 0.650 |
Why?
|
| Cooperative Behavior | 2 | 2019 | 229 | 0.630 |
Why?
|
| Sexual Harassment | 1 | 2020 | 16 | 0.620 |
Why?
|
| Research Support as Topic | 2 | 2019 | 42 | 0.620 |
Why?
|
| Accreditation | 4 | 2018 | 76 | 0.610 |
Why?
|
| Drug Industry | 1 | 2019 | 41 | 0.580 |
Why?
|
| Anticoagulants | 5 | 2022 | 525 | 0.560 |
Why?
|
| Workplace | 1 | 2020 | 179 | 0.560 |
Why?
|
| Disclosure | 2 | 2019 | 57 | 0.550 |
Why?
|
| Surgery Department, Hospital | 2 | 2013 | 19 | 0.550 |
Why?
|
| Faculty, Medical | 4 | 2021 | 201 | 0.550 |
Why?
|
| Quality of Health Care | 4 | 2017 | 528 | 0.540 |
Why?
|
| Adult | 53 | 2021 | 17358 | 0.540 |
Why?
|
| Bariatric Surgery | 2 | 2017 | 65 | 0.530 |
Why?
|
| Middle Aged | 58 | 2022 | 18273 | 0.520 |
Why?
|
| Risk Assessment | 6 | 2025 | 2102 | 0.510 |
Why?
|
| Postoperative Complications | 13 | 2022 | 1322 | 0.500 |
Why?
|
| Medicare | 2 | 2020 | 624 | 0.480 |
Why?
|
| Aged | 45 | 2022 | 14963 | 0.480 |
Why?
|
| Health Personnel | 2 | 2020 | 385 | 0.470 |
Why?
|
| Work Schedule Tolerance | 2 | 2017 | 22 | 0.470 |
Why?
|
| Length of Stay | 12 | 2020 | 827 | 0.460 |
Why?
|
| Cultural Diversity | 3 | 2021 | 54 | 0.450 |
Why?
|
| Hospitals, Public | 1 | 2015 | 7 | 0.450 |
Why?
|
| Equipment and Supplies | 1 | 2015 | 19 | 0.440 |
Why?
|
| Informed Consent | 1 | 2016 | 141 | 0.440 |
Why?
|
| NF-kappa B | 3 | 2006 | 434 | 0.430 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 235 | 0.420 |
Why?
|
| Abdominal Injuries | 1 | 2014 | 32 | 0.420 |
Why?
|
| Sleep | 1 | 2017 | 240 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 706 | 0.420 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2021 | 90 | 0.420 |
Why?
|
| Adolescent | 21 | 2025 | 6306 | 0.410 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2014 | 48 | 0.410 |
Why?
|
| Hyperglycemia | 2 | 2015 | 104 | 0.410 |
Why?
|
| Diverticulitis, Colonic | 3 | 2022 | 38 | 0.410 |
Why?
|
| American Heart Association | 2 | 2024 | 128 | 0.410 |
Why?
|
| Perioperative Care | 2 | 2024 | 87 | 0.400 |
Why?
|
| Colonic Neoplasms | 3 | 2023 | 220 | 0.400 |
Why?
|
| Diverticulitis | 3 | 2022 | 33 | 0.400 |
Why?
|
| Spleen | 1 | 2014 | 474 | 0.390 |
Why?
|
| Patient Readmission | 3 | 2022 | 448 | 0.390 |
Why?
|
| Clinical Clerkship | 2 | 2022 | 94 | 0.390 |
Why?
|
| Accountable Care Organizations | 1 | 2014 | 74 | 0.380 |
Why?
|
| Laparoscopy | 7 | 2017 | 490 | 0.380 |
Why?
|
| Gallstones | 4 | 2022 | 25 | 0.380 |
Why?
|
| Diabetes Mellitus | 4 | 2016 | 555 | 0.380 |
Why?
|
| Mental Disorders | 1 | 2020 | 822 | 0.370 |
Why?
|
| Education, Medical, Continuing | 3 | 2021 | 92 | 0.370 |
Why?
|
| History, 20th Century | 4 | 2016 | 232 | 0.360 |
Why?
|
| Liver | 7 | 2006 | 871 | 0.360 |
Why?
|
| Schools, Medical | 1 | 2013 | 150 | 0.360 |
Why?
|
| Pandemics | 6 | 2022 | 675 | 0.360 |
Why?
|
| Risk Factors | 13 | 2025 | 5430 | 0.360 |
Why?
|
| Warfarin | 2 | 2018 | 125 | 0.360 |
Why?
|
| Fellowships and Scholarships | 5 | 2021 | 106 | 0.360 |
Why?
|
| History, 21st Century | 3 | 2024 | 179 | 0.350 |
Why?
|
| Healthcare Disparities | 4 | 2016 | 407 | 0.350 |
Why?
|
| Injury Severity Score | 5 | 2019 | 117 | 0.340 |
Why?
|
| Benchmarking | 2 | 2023 | 137 | 0.340 |
Why?
|
| Surgicenters | 1 | 2011 | 9 | 0.340 |
Why?
|
| Utilization Review | 1 | 2011 | 32 | 0.340 |
Why?
|
| History, 19th Century | 3 | 2016 | 40 | 0.330 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2011 | 49 | 0.320 |
Why?
|
| Liver Neoplasms | 9 | 2014 | 309 | 0.320 |
Why?
|
| Trauma Centers | 6 | 2022 | 130 | 0.320 |
Why?
|
| Colectomy | 4 | 2022 | 123 | 0.310 |
Why?
|
| Colorectal Surgery | 1 | 2010 | 51 | 0.310 |
Why?
|
| Bile Duct Neoplasms | 8 | 1998 | 59 | 0.300 |
Why?
|
| Intestinal Obstruction | 2 | 1999 | 51 | 0.290 |
Why?
|
| Intestine, Small | 2 | 1999 | 82 | 0.290 |
Why?
|
| Medical Errors | 1 | 2011 | 202 | 0.290 |
Why?
|
| Tracheostomy | 2 | 2020 | 36 | 0.290 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 250 | 0.290 |
Why?
|
| Thyroidectomy | 2 | 2022 | 35 | 0.280 |
Why?
|
| Oncology Service, Hospital | 1 | 2008 | 3 | 0.280 |
Why?
|
| Colitis | 2 | 2019 | 77 | 0.270 |
Why?
|
| Adenocarcinoma | 5 | 2016 | 366 | 0.270 |
Why?
|
| Obesity | 2 | 2016 | 1273 | 0.260 |
Why?
|
| Medical Oncology | 1 | 2008 | 69 | 0.260 |
Why?
|
| Acute Disease | 8 | 2018 | 663 | 0.260 |
Why?
|
| Ethionine | 2 | 2006 | 2 | 0.260 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 2763 | 0.260 |
Why?
|
| New York | 4 | 2020 | 144 | 0.250 |
Why?
|
| STAT4 Transcription Factor | 1 | 2006 | 7 | 0.250 |
Why?
|
| STAT6 Transcription Factor | 1 | 2006 | 9 | 0.250 |
Why?
|
| Demography | 3 | 2021 | 178 | 0.250 |
Why?
|
| Choline Deficiency | 1 | 2006 | 14 | 0.250 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 863 | 0.250 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 433 | 0.250 |
Why?
|
| Clinical Competence | 5 | 2021 | 727 | 0.240 |
Why?
|
| Aged, 80 and over | 17 | 2020 | 5614 | 0.240 |
Why?
|
| Vascular Surgical Procedures | 3 | 2016 | 240 | 0.240 |
Why?
|
| Health Services Accessibility | 5 | 2016 | 593 | 0.240 |
Why?
|
| Medicine | 2 | 2020 | 55 | 0.240 |
Why?
|
| Thyroxine | 2 | 2018 | 55 | 0.230 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 1998 | 88 | 0.230 |
Why?
|
| History, 18th Century | 2 | 2016 | 8 | 0.230 |
Why?
|
| Registries | 5 | 2020 | 925 | 0.230 |
Why?
|
| Vascular System Injuries | 1 | 2025 | 22 | 0.230 |
Why?
|
| Committee Membership | 1 | 2025 | 8 | 0.230 |
Why?
|
| Aorta, Thoracic | 1 | 2025 | 80 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 464 | 0.230 |
Why?
|
| Thoracic Injuries | 1 | 2025 | 46 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 71 | 0.220 |
Why?
|
| Databases, Factual | 5 | 2020 | 882 | 0.220 |
Why?
|
| Leisure Activities | 1 | 2005 | 26 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 6 | 2014 | 354 | 0.220 |
Why?
|
| Survival Rate | 10 | 2010 | 844 | 0.220 |
Why?
|
| Education, Distance | 1 | 2005 | 35 | 0.210 |
Why?
|
| Communicable Disease Control | 2 | 2022 | 40 | 0.210 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2018 | 228 | 0.210 |
Why?
|
| Quality Improvement | 5 | 2022 | 464 | 0.210 |
Why?
|
| Comorbidity | 5 | 2016 | 1119 | 0.210 |
Why?
|
| Young Adult | 5 | 2020 | 4812 | 0.200 |
Why?
|
| Teaching | 1 | 2005 | 165 | 0.200 |
Why?
|
| Angiography | 5 | 2014 | 154 | 0.200 |
Why?
|
| Endotoxins | 1 | 2003 | 81 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2018 | 1656 | 0.190 |
Why?
|
| Diet | 1 | 2006 | 536 | 0.190 |
Why?
|
| Cohort Studies | 7 | 2020 | 2619 | 0.190 |
Why?
|
| Lymphoma | 1 | 2023 | 101 | 0.190 |
Why?
|
| Wounds, Stab | 2 | 2002 | 13 | 0.190 |
Why?
|
| Age Factors | 5 | 2025 | 1585 | 0.190 |
Why?
|
| Physicians | 3 | 2017 | 477 | 0.180 |
Why?
|
| Laryngeal Diseases | 1 | 2002 | 2 | 0.180 |
Why?
|
| Larynx | 1 | 2002 | 15 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2016 | 117 | 0.180 |
Why?
|
| Adenoma | 2 | 2006 | 70 | 0.180 |
Why?
|
| Tracheal Diseases | 1 | 2002 | 11 | 0.180 |
Why?
|
| Wounds, Gunshot | 2 | 2002 | 48 | 0.180 |
Why?
|
| Health Status | 2 | 2020 | 447 | 0.180 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2023 | 161 | 0.180 |
Why?
|
| Cholecystectomy | 3 | 2015 | 34 | 0.180 |
Why?
|
| Governing Board | 1 | 2021 | 3 | 0.180 |
Why?
|
| Child | 9 | 2025 | 4612 | 0.180 |
Why?
|
| Job Application | 1 | 2021 | 7 | 0.180 |
Why?
|
| Treatment Outcome | 12 | 2022 | 5790 | 0.170 |
Why?
|
| Natural Science Disciplines | 1 | 2021 | 1 | 0.170 |
Why?
|
| Multiple Trauma | 2 | 2019 | 29 | 0.170 |
Why?
|
| Logistic Models | 5 | 2018 | 1270 | 0.170 |
Why?
|
| Trachea | 1 | 2002 | 83 | 0.170 |
Why?
|
| Colon | 2 | 2019 | 147 | 0.170 |
Why?
|
| Civil Rights | 1 | 2021 | 20 | 0.170 |
Why?
|
| Cholecystectomy, Laparoscopic | 3 | 1999 | 49 | 0.170 |
Why?
|
| Anesthetics, Local | 2 | 2020 | 73 | 0.170 |
Why?
|
| Pain Management | 2 | 2020 | 174 | 0.170 |
Why?
|
| Disaster Planning | 1 | 2021 | 56 | 0.170 |
Why?
|
| Peritoneal Dialysis | 1 | 2020 | 13 | 0.160 |
Why?
|
| Checklist | 1 | 2021 | 72 | 0.160 |
Why?
|
| Career Mobility | 1 | 2021 | 63 | 0.160 |
Why?
|
| Hernia, Abdominal | 1 | 2020 | 9 | 0.160 |
Why?
|
| Embolization, Therapeutic | 5 | 2014 | 333 | 0.160 |
Why?
|
| Surgical Oncology | 1 | 2020 | 6 | 0.160 |
Why?
|
| Lidocaine | 1 | 2020 | 33 | 0.160 |
Why?
|
| Splenectomy | 3 | 2014 | 39 | 0.160 |
Why?
|
| Catheterization, Peripheral | 1 | 2020 | 50 | 0.160 |
Why?
|
| Pancreatic Diseases | 1 | 2000 | 38 | 0.160 |
Why?
|
| Adenoma, Bile Duct | 5 | 1993 | 8 | 0.160 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 71 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2022 | 189 | 0.150 |
Why?
|
| Appendix | 1 | 1999 | 17 | 0.150 |
Why?
|
| Research | 1 | 2021 | 194 | 0.150 |
Why?
|
| Ultrasonography, Doppler | 1 | 1999 | 27 | 0.150 |
Why?
|
| Arteries | 2 | 1991 | 81 | 0.150 |
Why?
|
| Chemokine CXCL10 | 1 | 2019 | 56 | 0.150 |
Why?
|
| Cholangitis | 2 | 1999 | 12 | 0.150 |
Why?
|
| Incidence | 5 | 2020 | 1419 | 0.150 |
Why?
|
| Abscess | 1 | 2000 | 78 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 104 | 0.150 |
Why?
|
| Safety | 1 | 2020 | 143 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 1998 | 176 | 0.150 |
Why?
|
| Interleukin-17 | 1 | 2019 | 99 | 0.150 |
Why?
|
| Contusions | 1 | 2019 | 10 | 0.150 |
Why?
|
| Polyglactin 910 | 1 | 2018 | 5 | 0.140 |
Why?
|
| Appendicitis | 1 | 1999 | 84 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2000 | 183 | 0.140 |
Why?
|
| Ultrasonography, Mammary | 1 | 1998 | 19 | 0.140 |
Why?
|
| Lung Injury | 1 | 2019 | 36 | 0.140 |
Why?
|
| Hypertriglyceridemia | 1 | 2018 | 9 | 0.140 |
Why?
|
| Pancreas | 3 | 2006 | 154 | 0.140 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 627 | 0.140 |
Why?
|
| Hypertension, Portal | 2 | 2005 | 19 | 0.140 |
Why?
|
| Hospital Planning | 1 | 2018 | 1 | 0.140 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 2293 | 0.140 |
Why?
|
| Students | 1 | 2020 | 225 | 0.140 |
Why?
|
| Mice | 10 | 2018 | 11114 | 0.140 |
Why?
|
| Neoplasm Staging | 7 | 2023 | 544 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2018 | 110 | 0.140 |
Why?
|
| Critical Care | 2 | 2018 | 402 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2000 | 223 | 0.140 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 53 | 0.140 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 527 | 0.140 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 139 | 0.130 |
Why?
|
| Personnel Selection | 1 | 2018 | 57 | 0.130 |
Why?
|
| Abdominal Muscles | 1 | 2017 | 8 | 0.130 |
Why?
|
| Organizational Culture | 2 | 2018 | 115 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 1994 | 28 | 0.130 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 249 | 0.130 |
Why?
|
| Bupivacaine | 1 | 2017 | 31 | 0.130 |
Why?
|
| Interferon-gamma | 1 | 2019 | 574 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 2704 | 0.130 |
Why?
|
| United Kingdom | 1 | 2017 | 85 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.130 |
Why?
|
| Cryosurgery | 1 | 1997 | 28 | 0.130 |
Why?
|
| Aneurysm, Ruptured | 1 | 2018 | 82 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2018 | 134 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.130 |
Why?
|
| Phlebitis | 1 | 1996 | 2 | 0.130 |
Why?
|
| Thrombophlebitis | 1 | 1996 | 14 | 0.130 |
Why?
|
| Regional Health Planning | 1 | 2016 | 10 | 0.120 |
Why?
|
| Inpatients | 2 | 2020 | 318 | 0.120 |
Why?
|
| Infant | 3 | 2025 | 1693 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2025 | 2061 | 0.120 |
Why?
|
| Hepatic Artery | 1 | 1996 | 22 | 0.120 |
Why?
|
| Efficiency | 1 | 2016 | 39 | 0.120 |
Why?
|
| Curriculum | 3 | 2022 | 608 | 0.120 |
Why?
|
| Th17 Cells | 1 | 2016 | 61 | 0.120 |
Why?
|
| Nerve Block | 1 | 2017 | 61 | 0.120 |
Why?
|
| Hemorrhage | 2 | 1996 | 285 | 0.120 |
Why?
|
| Aortic Rupture | 1 | 2016 | 47 | 0.120 |
Why?
|
| Stomach Neoplasms | 2 | 1997 | 81 | 0.120 |
Why?
|
| DNA Damage | 1 | 2018 | 298 | 0.120 |
Why?
|
| Obstetric Labor Complications | 1 | 1996 | 23 | 0.120 |
Why?
|
| Flail Chest | 1 | 2015 | 3 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 414 | 0.120 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 5 | 2000 | 49 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 3481 | 0.120 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1996 | 38 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 1113 | 0.120 |
Why?
|
| Animals | 13 | 2019 | 21333 | 0.120 |
Why?
|
| Choledochal Cyst | 1 | 1995 | 3 | 0.120 |
Why?
|
| Colon, Sigmoid | 1 | 2015 | 13 | 0.120 |
Why?
|
| Diverticulum | 1 | 2015 | 12 | 0.120 |
Why?
|
| Ceruletide | 2 | 2006 | 5 | 0.110 |
Why?
|
| Certification | 1 | 2016 | 58 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 1997 | 182 | 0.110 |
Why?
|
| Fracture Fixation, Internal | 1 | 2015 | 66 | 0.110 |
Why?
|
| Follow-Up Studies | 7 | 2022 | 2484 | 0.110 |
Why?
|
| Interpersonal Relations | 1 | 2016 | 160 | 0.110 |
Why?
|
| Poisson Distribution | 1 | 2015 | 52 | 0.110 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2018 | 276 | 0.110 |
Why?
|
| Peroxidase | 2 | 2006 | 70 | 0.110 |
Why?
|
| Liver Diseases | 1 | 1996 | 158 | 0.110 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2014 | 27 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2015 | 64 | 0.110 |
Why?
|
| Cholangiocarcinoma | 2 | 1994 | 35 | 0.110 |
Why?
|
| Truth Disclosure | 1 | 2015 | 58 | 0.110 |
Why?
|
| Group Processes | 1 | 2014 | 41 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2005 | 1222 | 0.100 |
Why?
|
| Sensitivity and Specificity | 6 | 2004 | 1163 | 0.100 |
Why?
|
| Sex Factors | 2 | 2016 | 991 | 0.100 |
Why?
|
| Wounds, Penetrating | 2 | 1994 | 33 | 0.100 |
Why?
|
| Heparin | 1 | 2014 | 118 | 0.100 |
Why?
|
| Bias | 1 | 2014 | 115 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2016 | 493 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 930 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 235 | 0.100 |
Why?
|
| Prognosis | 6 | 2023 | 1785 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2018 | 1036 | 0.100 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 528 | 0.100 |
Why?
|
| Mentors | 2 | 2016 | 119 | 0.100 |
Why?
|
| Intraoperative Complications | 2 | 2005 | 88 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2015 | 497 | 0.090 |
Why?
|
| Drainage | 5 | 1995 | 152 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2018 | 576 | 0.090 |
Why?
|
| Cardiology | 2 | 2024 | 170 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 169 | 0.090 |
Why?
|
| Rural Health Services | 1 | 2012 | 34 | 0.090 |
Why?
|
| Hospitals, Community | 3 | 2016 | 71 | 0.090 |
Why?
|
| Liver Abscess | 1 | 1991 | 18 | 0.090 |
Why?
|
| SEER Program | 2 | 2010 | 75 | 0.090 |
Why?
|
| Patient Safety | 3 | 2020 | 259 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2015 | 394 | 0.090 |
Why?
|
| Sphincterotomy, Transduodenal | 1 | 1991 | 4 | 0.090 |
Why?
|
| Ticlopidine | 1 | 2011 | 47 | 0.090 |
Why?
|
| Common Bile Duct | 1 | 1991 | 21 | 0.090 |
Why?
|
| Thoracic Surgery | 1 | 2012 | 80 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 1290 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2023 | 252 | 0.080 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 69 | 0.080 |
Why?
|
| Physician Executives | 1 | 2011 | 28 | 0.080 |
Why?
|
| Splenic Vein | 1 | 1990 | 2 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2018 | 287 | 0.080 |
Why?
|
| Florida | 1 | 2011 | 46 | 0.080 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1990 | 15 | 0.080 |
Why?
|
| Cholangiography | 4 | 1998 | 43 | 0.080 |
Why?
|
| Surgery, Plastic | 1 | 2011 | 19 | 0.080 |
Why?
|
| Suppuration | 3 | 1996 | 11 | 0.080 |
Why?
|
| Neoplasms | 2 | 2012 | 1367 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2012 | 147 | 0.080 |
Why?
|
| Aspirin | 1 | 2011 | 172 | 0.080 |
Why?
|
| Blood Transfusion | 2 | 2010 | 164 | 0.080 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 801 | 0.080 |
Why?
|
| Mass Screening | 2 | 2006 | 698 | 0.080 |
Why?
|
| Anesthesia | 1 | 2010 | 52 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 252 | 0.080 |
Why?
|
| Lung | 2 | 2006 | 964 | 0.080 |
Why?
|
| Learning | 2 | 2021 | 186 | 0.070 |
Why?
|
| Hospitals | 1 | 2012 | 386 | 0.070 |
Why?
|
| Role Playing | 1 | 2008 | 8 | 0.070 |
Why?
|
| Anastomosis, Surgical | 3 | 1995 | 118 | 0.070 |
Why?
|
| Tennessee | 3 | 2006 | 17 | 0.070 |
Why?
|
| Minority Health | 1 | 2008 | 6 | 0.070 |
Why?
|
| Liver Transplantation | 2 | 2005 | 220 | 0.070 |
Why?
|
| Thrombosis | 1 | 1990 | 206 | 0.070 |
Why?
|
| Cholelithiasis | 2 | 1999 | 23 | 0.070 |
Why?
|
| Tertiary Care Centers | 2 | 2020 | 111 | 0.070 |
Why?
|
| Radiography, Interventional | 2 | 2000 | 82 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2010 | 261 | 0.060 |
Why?
|
| Colonoscopy | 2 | 2006 | 97 | 0.060 |
Why?
|
| Electrosurgery | 1 | 2006 | 5 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 1997 | 24 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2013 | 544 | 0.060 |
Why?
|
| Health Services Research | 1 | 2008 | 265 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 25 | 0.060 |
Why?
|
| Suction | 2 | 2000 | 33 | 0.060 |
Why?
|
| Sigmoidoscopy | 1 | 2006 | 16 | 0.060 |
Why?
|
| Time Factors | 6 | 2020 | 3762 | 0.060 |
Why?
|
| Cytokines | 2 | 2016 | 952 | 0.060 |
Why?
|
| Occult Blood | 1 | 2006 | 19 | 0.060 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 1996 | 5 | 0.060 |
Why?
|
| Inflammation | 2 | 2018 | 1187 | 0.060 |
Why?
|
| Social Class | 2 | 2023 | 137 | 0.060 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2005 | 9 | 0.060 |
Why?
|
| Bile Ducts | 1 | 2005 | 26 | 0.060 |
Why?
|
| Peptic Ulcer | 1 | 2005 | 18 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 450 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2011 | 602 | 0.060 |
Why?
|
| CpG Islands | 1 | 2006 | 219 | 0.060 |
Why?
|
| Decompression, Surgical | 1 | 2005 | 70 | 0.060 |
Why?
|
| Gastric Bypass | 1 | 2005 | 69 | 0.060 |
Why?
|
| Cholestasis | 2 | 1998 | 65 | 0.060 |
Why?
|
| Gastroesophageal Reflux | 1 | 2005 | 93 | 0.060 |
Why?
|
| Videoconferencing | 1 | 2005 | 10 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 869 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 1998 | 74 | 0.050 |
Why?
|
| Feasibility Studies | 3 | 1997 | 587 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2005 | 742 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2025 | 140 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2006 | 302 | 0.050 |
Why?
|
| Hepatectomy | 3 | 1993 | 63 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2006 | 236 | 0.050 |
Why?
|
| Ligation | 2 | 1996 | 37 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2010 | 91 | 0.050 |
Why?
|
| Reperfusion | 1 | 2004 | 37 | 0.050 |
Why?
|
| France | 1 | 2023 | 14 | 0.050 |
Why?
|
| Switzerland | 1 | 2023 | 17 | 0.050 |
Why?
|
| Ischemia | 2 | 2004 | 203 | 0.050 |
Why?
|
| Tyrosine | 1 | 2004 | 93 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2023 | 45 | 0.050 |
Why?
|
| Luminescent Measurements | 1 | 2003 | 40 | 0.050 |
Why?
|
| Popliteal Artery | 2 | 1994 | 24 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2003 | 91 | 0.050 |
Why?
|
| Cell Count | 1 | 2003 | 128 | 0.050 |
Why?
|
| HIV-1 | 2 | 2000 | 706 | 0.050 |
Why?
|
| Luciferases | 1 | 2003 | 107 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 639 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 327 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2004 | 222 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2023 | 232 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 39 | 0.040 |
Why?
|
| Disease Progression | 3 | 2018 | 1219 | 0.040 |
Why?
|
| Women's Rights | 1 | 2021 | 7 | 0.040 |
Why?
|
| Health Services Needs and Demand | 2 | 2014 | 219 | 0.040 |
Why?
|
| Human Rights | 1 | 2021 | 17 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 27 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1141 | 0.040 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2000 | 7 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 222 | 0.040 |
Why?
|
| Duodenum | 1 | 2000 | 41 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2020 | 31 | 0.040 |
Why?
|
| Leucovorin | 3 | 1997 | 8 | 0.040 |
Why?
|
| Constriction, Pathologic | 3 | 1995 | 130 | 0.040 |
Why?
|
| Palliative Care | 2 | 1993 | 249 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2000 | 801 | 0.040 |
Why?
|
| Pneumonia | 1 | 2003 | 291 | 0.040 |
Why?
|
| Cellular Microenvironment | 1 | 2019 | 23 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2019 | 35 | 0.040 |
Why?
|
| Tissue Culture Techniques | 1 | 2019 | 33 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2000 | 67 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2020 | 126 | 0.040 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2020 | 36 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2018 | 137 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 105 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2019 | 51 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2000 | 93 | 0.040 |
Why?
|
| Cause of Death | 1 | 2000 | 221 | 0.040 |
Why?
|
| Outpatients | 1 | 2020 | 142 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2020 | 113 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 208 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 149 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 372 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2019 | 3149 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 3 | 0.040 |
Why?
|
| Stents | 2 | 1993 | 498 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2018 | 28 | 0.040 |
Why?
|
| Azoxymethane | 1 | 2018 | 15 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 198 | 0.040 |
Why?
|
| Technetium | 1 | 1998 | 68 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2018 | 49 | 0.040 |
Why?
|
| Prospective Studies | 2 | 1999 | 3310 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 1998 | 128 | 0.040 |
Why?
|
| Anastomosis, Roux-en-Y | 2 | 1995 | 4 | 0.040 |
Why?
|
| Postoperative Care | 2 | 2016 | 125 | 0.040 |
Why?
|
| Carcinoma, Lobular | 1 | 1998 | 26 | 0.030 |
Why?
|
| Occupational Health | 1 | 2020 | 193 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 1998 | 90 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 2018 | 39 | 0.030 |
Why?
|
| Aldehyde Reductase | 1 | 1998 | 3 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 1998 | 36 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1998 | 44 | 0.030 |
Why?
|
| Social Justice | 1 | 2018 | 33 | 0.030 |
Why?
|
| Osteopathic Medicine | 1 | 2018 | 9 | 0.030 |
Why?
|
| Cystic Duct | 1 | 1998 | 5 | 0.030 |
Why?
|
| Lipase | 1 | 2018 | 52 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 203 | 0.030 |
Why?
|
| Bilirubin | 2 | 1994 | 19 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 178 | 0.030 |
Why?
|
| Erythrocytes | 1 | 1998 | 146 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2018 | 111 | 0.030 |
Why?
|
| Alkaline Phosphatase | 2 | 1994 | 46 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 127 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2018 | 391 | 0.030 |
Why?
|
| Recurrence | 2 | 1999 | 657 | 0.030 |
Why?
|
| Energy Intake | 1 | 2018 | 173 | 0.030 |
Why?
|
| Sepsis | 2 | 1991 | 296 | 0.030 |
Why?
|
| Floxuridine | 2 | 1997 | 5 | 0.030 |
Why?
|
| Infusions, Parenteral | 2 | 1997 | 21 | 0.030 |
Why?
|
| Biomarkers | 2 | 2018 | 1480 | 0.030 |
Why?
|
| Liposomes | 1 | 2017 | 116 | 0.030 |
Why?
|
| Intestines | 1 | 2018 | 178 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 962 | 0.030 |
Why?
|
| Biopsy | 1 | 1998 | 456 | 0.030 |
Why?
|
| Triglycerides | 1 | 2018 | 248 | 0.030 |
Why?
|
| Methionine Adenosyltransferase | 1 | 1996 | 7 | 0.030 |
Why?
|
| Fluorouracil | 2 | 1997 | 68 | 0.030 |
Why?
|
| Breast | 1 | 1998 | 191 | 0.030 |
Why?
|
| Zalcitabine | 1 | 1996 | 2 | 0.030 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1996 | 8 | 0.030 |
Why?
|
| Antiemetics | 1 | 2017 | 97 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 1996 | 23 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 1997 | 175 | 0.030 |
Why?
|
| Publishing | 1 | 2018 | 95 | 0.030 |
Why?
|
| Reoperation | 3 | 1994 | 301 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 1996 | 12 | 0.030 |
Why?
|
| Hemostasis, Surgical | 1 | 1996 | 21 | 0.030 |
Why?
|
| Cisplatin | 2 | 1997 | 147 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 1997 | 296 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 345 | 0.030 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2016 | 20 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2016 | 58 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1259 | 0.030 |
Why?
|
| Mammography | 1 | 1998 | 290 | 0.030 |
Why?
|
| Duodenostomy | 1 | 1995 | 1 | 0.030 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 1995 | 1 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1996 | 129 | 0.030 |
Why?
|
| Jejunostomy | 1 | 1995 | 7 | 0.030 |
Why?
|
| Common Bile Duct Diseases | 1 | 1995 | 10 | 0.030 |
Why?
|
| Laparoscopes | 1 | 1995 | 23 | 0.030 |
Why?
|
| Visual Perception | 1 | 1995 | 46 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 119 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 875 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 1999 | 385 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1996 | 323 | 0.030 |
Why?
|
| Leg Injuries | 1 | 1994 | 16 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 1994 | 38 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 1994 | 35 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 1994 | 46 | 0.030 |
Why?
|
| Soft Tissue Injuries | 1 | 1994 | 20 | 0.030 |
Why?
|
| Catheterization | 2 | 1993 | 111 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 2156 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 426 | 0.030 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 1994 | 8 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 1996 | 321 | 0.020 |
Why?
|
| International Educational Exchange | 1 | 1993 | 2 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2013 | 24 | 0.020 |
Why?
|
| Apoptosis | 1 | 2018 | 1100 | 0.020 |
Why?
|
| Choledochostomy | 1 | 1992 | 3 | 0.020 |
Why?
|
| Hemangioma, Cavernous | 1 | 1992 | 9 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 298 | 0.020 |
Why?
|
| Hospitalization | 1 | 2000 | 1392 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1995 | 261 | 0.020 |
Why?
|
| Pregnancy | 2 | 1999 | 2374 | 0.020 |
Why?
|
| Phlebography | 1 | 1992 | 45 | 0.020 |
Why?
|
| Dissection | 1 | 1993 | 46 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 427 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 240 | 0.020 |
Why?
|
| Foreign Medical Graduates | 1 | 2012 | 3 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 140 | 0.020 |
Why?
|
| Training Support | 1 | 2012 | 20 | 0.020 |
Why?
|
| Military Medicine | 1 | 2012 | 32 | 0.020 |
Why?
|
| Virginia | 1 | 2011 | 27 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1630 | 0.020 |
Why?
|
| Blood Loss, Surgical | 3 | 1999 | 65 | 0.020 |
Why?
|
| Cholecystitis | 1 | 1991 | 29 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 861 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2012 | 127 | 0.020 |
Why?
|
| Iliac Artery | 1 | 1991 | 43 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 1990 | 17 | 0.020 |
Why?
|
| Sclerotherapy | 1 | 1990 | 9 | 0.020 |
Why?
|
| Random Allocation | 1 | 1991 | 200 | 0.020 |
Why?
|
| Endoscopy | 1 | 1991 | 95 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 59 | 0.020 |
Why?
|
| Aorta | 1 | 1991 | 108 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 1990 | 99 | 0.020 |
Why?
|
| Femoral Artery | 1 | 1991 | 104 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 583 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1991 | 150 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1991 | 214 | 0.020 |
Why?
|
| Vertebral Artery | 1 | 1989 | 29 | 0.020 |
Why?
|
| Pilot Projects | 1 | 1992 | 1016 | 0.020 |
Why?
|
| Hemostatic Techniques | 1 | 1988 | 12 | 0.020 |
Why?
|
| Sutures | 1 | 1988 | 39 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1566 | 0.020 |
Why?
|
| Mortality | 1 | 1988 | 161 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2006 | 26 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2006 | 31 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2006 | 122 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 1048 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2006 | 75 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2004 | 1559 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 1998 | 373 | 0.010 |
Why?
|
| International Classification of Diseases | 1 | 2006 | 136 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 2005 | 44 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2005 | 55 | 0.010 |
Why?
|
| Health Surveys | 1 | 2006 | 317 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 244 | 0.010 |
Why?
|
| Preoperative Care | 2 | 1996 | 199 | 0.010 |
Why?
|
| Gallbladder Neoplasms | 2 | 1994 | 14 | 0.010 |
Why?
|
| Reperfusion Injury | 1 | 2004 | 57 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 134 | 0.010 |
Why?
|
| Health Behavior | 1 | 2006 | 484 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2004 | 321 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 896 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1998 | 1575 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 1282 | 0.010 |
Why?
|
| Fetal Monitoring | 1 | 1999 | 7 | 0.010 |
Why?
|
| Dilatation | 1 | 1999 | 34 | 0.010 |
Why?
|
| Radiography | 2 | 1992 | 555 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1998 | 152 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 165 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 513 | 0.010 |
Why?
|
| Vincristine | 1 | 1996 | 26 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1996 | 17 | 0.010 |
Why?
|
| Bleomycin | 1 | 1996 | 35 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1996 | 202 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1996 | 28 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1996 | 84 | 0.010 |
Why?
|
| Remission Induction | 1 | 1996 | 149 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1996 | 129 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1996 | 98 | 0.010 |
Why?
|
| Methotrexate | 1 | 1996 | 80 | 0.010 |
Why?
|
| Operating Room Nursing | 1 | 1995 | 4 | 0.010 |
Why?
|
| Individuality | 1 | 1995 | 24 | 0.010 |
Why?
|
| Allied Health Personnel | 1 | 1995 | 26 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1996 | 624 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1996 | 213 | 0.010 |
Why?
|
| Gynecology | 1 | 1995 | 55 | 0.010 |
Why?
|
| Fasciotomy | 1 | 1994 | 11 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 1589 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 1979 | 0.010 |
Why?
|
| Wound Infection | 1 | 1994 | 29 | 0.010 |
Why?
|
| Swine | 1 | 1995 | 394 | 0.010 |
Why?
|
| Vascular Patency | 1 | 1994 | 134 | 0.010 |
Why?
|
| Patient Selection | 1 | 1996 | 485 | 0.010 |
Why?
|
| Biliary Fistula | 1 | 1993 | 4 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 17 | 0.010 |
Why?
|
| Stainless Steel | 1 | 1993 | 14 | 0.010 |
Why?
|
| Methods | 1 | 1992 | 40 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 1994 | 0.010 |
Why?
|
| Australia | 1 | 1993 | 130 | 0.010 |
Why?
|
| Mesenteric Artery, Superior | 1 | 1992 | 16 | 0.010 |
Why?
|
| Celiac Artery | 1 | 1992 | 13 | 0.010 |
Why?
|
| Portal Vein | 1 | 1992 | 39 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 907 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1996 | 2188 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1993 | 136 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1996 | 1698 | 0.010 |
Why?
|
| Equipment Design | 1 | 1993 | 363 | 0.010 |
Why?
|
| Water | 1 | 1993 | 314 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1992 | 489 | 0.000 |
Why?
|